Under the aegis of its Quality of Care Committee, the American College of Rheumatology (ACR) is a periodically commissions the development of RA Treatment Guidelines. The last RA Treatment Guideline update was published in 2012 and a fully revised RA Treatment Guideline is under current development. In the past, the ACR has recommended the use of the RAND/UCLA appropriateness method. Currently, the methods being used is GRADE. Both methods require a formal literature synthesis. Differences in guidelines resulting from the two processes will be discussed. ACR RA Treatment Guidelines continue to focus on recommendations for the use of both biologic and non-biologic DMARDs based on therapeutic efficacy and safety considerations. New ACR RA guidelines will also consider the role of glucocorticiods in RA management.
Disclosure of Interest K. Saag Consultant for: Abbott, Amgen, Crescendo, Novartis, Roche,
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.